More than one-third of the worldwide population is overweight or obese and therefore at risk
of developing type 2 diabetes mellitus. In order to mitigate this pandemic, safer and more …

Obesity or excessive weight gain is identified as the most important and significant risk factor
in the development and progression of type 2 diabetes mellitus (DM) in all age groups. It has …

Objective Vertical sleeve gastrectomy (VSG) produces high rates of type 2 diabetes
remission; however, the mechanisms responsible remain incompletely defined. VSG …

Glucagon like peptide-1 (GLP-1) is a hormone produced and released by cells of the
gastrointestinal tract following meal ingestion. GLP-1 receptor agonists (GLP-1RA) exhibit …

Obesity and obesity-related metabolic diseases represent a growing socioeconomic
problem throughout the world. Great emphasis has been put on establishing treatments for …

The liver and intestine have complementary and coordinated roles in lipoprotein
metabolism. Despite their highly specialized functions, assembly and secretion of …

Dyslipidemia is a potent risk factor for the genesis and progression of cardiovascular
disease (CVD), and both the concentration and type of low-density lipoproteins (LDL) …

Long-acting glucagon-like peptide-1 (GLP-1) analogues marketed for type 2 diabetes (T2D)
treatment have been showing positive and protective effects in several different tissues …

摘要背景除了可以降解胰高血糖素肽‐1 (GLP‐1), 二肽基肽酶‐4 (DPP‐4) 还可以灭活几种趋化
因子, 包括间质细胞衍生因子‐1α (stromal cell‐derived factor‐1α, SDF‐1α) …

Introduction The glucagon-like peptide-1 agonist (GLP1-RA) liraglutide is currently approved
for the treatment of both obesity and type 2 diabetes (T2DM). We investigated whether the …